Wall Street analysts forecast that Henry Schein, Inc. (NASDAQ:HSIC) will report sales of $3.36 billion for the current fiscal quarter, Zacks reports. Ten analysts have issued estimates for Henry Schein’s earnings, with estimates ranging from $3.33 billion to $3.40 billion. Henry Schein reported sales of $3.16 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The company is expected to issue its next earnings results on Monday, November 5th.
According to Zacks, analysts expect that Henry Schein will report full year sales of $13.39 billion for the current fiscal year, with estimates ranging from $13.32 billion to $13.47 billion. For the next year, analysts expect that the business will report sales of $14.03 billion, with estimates ranging from $13.78 billion to $14.25 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Henry Schein.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Monday, August 6th. The company reported $1.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.03. Henry Schein had a return on equity of 20.40% and a net margin of 3.15%. The business had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.31 billion. During the same period in the previous year, the business earned $0.88 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis.
A number of brokerages have recently weighed in on HSIC. BidaskClub upgraded Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday. ValuEngine upgraded Henry Schein from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a report on Friday. Robert W. Baird boosted their price target on Henry Schein from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Cleveland Research reiterated a “hold” rating on shares of Henry Schein in a report on Monday, September 24th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Henry Schein currently has an average rating of “Hold” and a consensus target price of $85.06.
Shares of NASDAQ HSIC traded up $1.19 during trading on Tuesday, reaching $88.44. The stock had a trading volume of 2,898,188 shares, compared to its average volume of 1,574,212. Henry Schein has a one year low of $62.56 and a one year high of $90.52. The company has a current ratio of 1.29, a quick ratio of 0.68 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $13.02 billion, a price-to-earnings ratio of 24.57, a price-to-earnings-growth ratio of 2.45 and a beta of 0.97.
Institutional investors and hedge funds have recently modified their holdings of the stock. Squar Milner Financial Services LLC bought a new position in Henry Schein during the 2nd quarter worth $120,000. Piedmont Investment Advisors LLC bought a new position in Henry Schein during the 2nd quarter worth $130,000. Fuller & Thaler Asset Management Inc. grew its stake in Henry Schein by 57.1% during the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after buying an additional 800 shares during the last quarter. BerganKDV Wealth Management LLC bought a new position in Henry Schein during the 2nd quarter worth $203,000. Finally, Quest Investment Management LLC bought a new position in Henry Schein during the 2nd quarter worth $214,000. Hedge funds and other institutional investors own 96.65% of the company’s stock.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.